fbpx
Wikipedia

Lexatumumab

Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.[1][2]

Lexatumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTRAIL-R2
Clinical data
ATC code
  • none
Identifiers
CAS Number
  • 845816-02-6 N
ChemSpider
  • none
UNII
  • 967Q0SJD77
KEGG
  • D06611 Y
Chemical and physical data
FormulaC6346H9832N1720O2002S42
Molar mass143601.02 g·mol−1
 NY (what is this?)  (verify)

HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology.[3]

Development was discontinued in 2015.[4]

References edit

  1. ^ (PDF). American Medical Association. Archived from the original (PDF) on 2012-02-20.
  2. ^ Marini P (December 2006). "Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2". Current Opinion in Molecular Therapeutics. 8 (6): 539–46. PMID 17243490.
  3. ^ "TRAIL Receptor Antibodies". Human Genome Sciences, Inc. Archived from the original on 2008-05-16. Retrieved 2010-05-12.
  4. ^ "Lexatumumab". AdisInsight. Springer Nature Switzerland AG.


lexatumumab, also, known, etr2, st01, experimental, agonistic, human, monoclonal, antibody, against, trail, intended, treatment, cancer, monoclonal, antibodytypewhole, antibodysourcehumantargettrail, r2clinical, dataatc, codenoneidentifierscas, number845816, n. Lexatumumab also known as ETR2 ST01 is an experimental agonistic human monoclonal antibody against TRAIL R2 DR5 APO 2 intended for the treatment of cancer 1 2 LexatumumabMonoclonal antibodyTypeWhole antibodySourceHumanTargetTRAIL R2Clinical dataATC codenoneIdentifiersCAS Number845816 02 6 NChemSpidernoneUNII967Q0SJD77KEGGD06611 YChemical and physical dataFormulaC 6346H 9832N 1720O 2002S 42Molar mass143601 02 g mol 1 N Y what is this verify HGS ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology 3 Development was discontinued in 2015 4 References edit Statement on a Nonproprietary Name adopted by the USAN Council Lexatumumab PDF American Medical Association Archived from the original PDF on 2012 02 20 Marini P December 2006 Drug evaluation lexatumumab an intravenous human agonistic mAb targeting TRAIL receptor 2 Current Opinion in Molecular Therapeutics 8 6 539 46 PMID 17243490 TRAIL Receptor Antibodies Human Genome Sciences Inc Archived from the original on 2008 05 16 Retrieved 2010 05 12 Lexatumumab AdisInsight Springer Nature Switzerland AG nbsp This monoclonal antibody related article is a stub You can help Wikipedia by expanding it vte nbsp This antineoplastic or immunomodulatory drug article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Lexatumumab amp oldid 1194243560, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.